Real Estate Development

ZZYL

ZZYL released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 108.84 M, actual EPS CNY -0.0105

ZZYL released FY2025 Annual Earnings on April 24 After-Market (BJT), actual revenue CNY 577.34 M, actual EPS CNY -0.06

ZZYL released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 144.21 M, actual EPS CNY -0.0487

ZZYL to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

ZZYL to Release FY2025 Earnings on April 25 After-Market (BJT)

ZZYL released FY2025 9 Months Earnings on October 30 Pre-Market (BJT), actual revenue CNY 433.13 M, actual EPS CNY -0.0169

ZZYL released FY2025 Q3 earnings on October 30 Pre-Market (BJT), actual revenue CNY 130.28 M, actual EPS CNY -0.0048

ZZYL to Release FY2025 Q3 Earnings on October 31, Pre-Market BJT

ZZYL released FY2025 Semi-Annual earnings on August 27 Pre-Market (BJT), actual revenue CNY 302.85 M, actual EPS CNY -0.0122

ZZYL released FY2025 Q2 earnings on August 27 Pre-Market (BJT), actual revenue CNY 161.39 M, actual EPS CNY -0.0032

ZZYL FY2025 Semi-Annual Earning Release on August 28, 2025 (BJT)

ST Zhongzhu Announces 2025 H1 Earnings Forecast

ST Zhongzhu reports a net loss of 17.78 million yuan in Q1 2025

ST Zhongzhu Q1 2025 Revenue Growth but Still Losses

ZZYL released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 141.46 M, actual EPS CNY -0.0089

ZZYL FY2025 Q1 Earnings Release Scheduled for April 30 After-Market BJT

ZZYL released FY2024 Q4 earnings on April 18 After-Market (BJT), actual revenue CNY 137.49 M, actual EPS CNY -0.2493

ZZYL released FY2024 Annual Earnings on April 18 After-Market (BJT), with actual revenue of CNY 521.39 M and EPS of CNY -0.31

ZZYL FY2024 Annual Earnings Release Scheduled for April 19, 2025, After-Market BJT

ZZYL released FY2024 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 132.13 M, actual EPS CNY -0.014

The bleeding disorder testing market is projected to grow from USD 109.2 billion in 2025 to USD 234.6 billion by 2036, with a CAGR of 7.2%. This growth is driven by rising demand for performance-grade diagnostic solutions, increased hospital procurement, and a focus on regulatory compliance. Key segments include reagents and consumables, with hemophilia A being the leading indication. Major growth regions include China, India, Germany, France, and the United States, as healthcare institutions prioritize reliable diagnostic systems.

MorningStar

Siemens Healthineers AG

Roche

Thermo Fisher Scentific

Abbott Laboratories

Horiba , Ltd.

Pfizer

Baxter

ROCHE HOLDINGS AG

FMI Reveals Bleeding Disorder Testing Market USD 117.1 Billion in 2026 to USD 234.6 Billion by 2036 Driven by Expanding Demand for Performance-Grade Diagnostic Solutions

Chinese rehabilitation robot manufacturers are expanding into international markets, leveraging technological advancements despite facing regulatory challenges. Experts highlight the rapid development of robot technology and the importance of partnerships for market entry. The global rehabilitation equipment market is projected to grow significantly, driven by an aging population and increasing health issues. Companies are adapting their strategies to meet varying market receptiveness, particularly in Europe and the U.S.

Yicai

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

600568

Zhongzhu Healthcare Holding Ltd, a penny stock with a market cap of CN¥5.48 billion, focuses on drug development in China. Despite being unprofitable, it has a sufficient cash runway and recently attracted investor interest with a 10.38% stake acquisition. The company generated CN¥570.62 million in revenue but has a negative return on equity of -32.97%. The article also highlights other penny stocks, including Nanfang Pump Industry and Wutong Holding Group, showcasing their financial health and growth potential amidst market volatility.

Simplywall

Discover Global Penny Stocks: Zhongzhu Healthcare HoldingLtd Leads Our Trio

ST ZZYL announced that in the first half of 2025, the operating revenue was 303 million yuan, a year-on-year increase of 20.29%. The net loss attributable to shareholders of the listed company was 24.1372 million yuan, a year-on-year narrowing of 63.04%. The basic earnings per share were -0.0122 yuan/share, a year-on-year increase of 63.03%

Zhitong

ST ZZYL: Net loss of 24.1372 million yuan in the first half of 2025, a year-on-year narrowing of 63.04%

On August 15th, ST ZZYL announced that the eighth meeting of the tenth board of directors approved the appointment of Liu Huiping as the company's vice president, with a term starting from the date of approval by the tenth board of directors until the completion of the re-election of the tenth board of directors

ST ZZYL: Appointed Liu Huiping as the company's vice president

603108

301159

688561

600588

36Kr learned that as of the time of publication, the medical information sector weakened, with ST ZZYL hitting the limit down, and Yonyou, Qi An Xin-U, Hongjing Technology, Runda Medical, SunwayWorld, and Weining Health also following the decline

36Kr

Runda Medical

SunwayWorld

Qi An Xin

Yonyou

GloryView

Winning Health

The medical information sector weakened, and ST ZZYL hit the limit down

ST ZZYL announced that its revenue for the first quarter of 2025 was 141 million yuan, a year-on-year increase of 8.81%; the net loss was 17.7799 million yuan, compared to a net loss of 22.8936 million yuan in the same period last year

ZZYL: Net loss of 17.7799 million yuan in the first quarter of 2025

According to the Zhitong Finance APP, ST ZZYL released its 2024 annual report, stating that the company's operating revenue for 2024 is 521 million yuan, a year-on-year decrease of 18.35%; the net loss attributable to shareholders of the listed company is 620 million yuan, with losses widening; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses is 624 million yuan, with losses widening; the basic loss per share is 0.3148 yuan/share

ST ZZYL released its 2024 annual performance, with a net loss attributable to the parent company of 620 million yuan, an expanded loss

According to the announcement from ST Zhongzhu, it is expected that the annual operating performance for 2024 will show a loss, with a net profit attributable to shareholders of the listed company estimated to be around -500 million to -700 million yuan. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses is also estimated to be around -500 million to -700 million yuan

ST Zhongzhu issued a profit warning, expecting a net loss of 500 million to 700 million yuan in 2024

ZZYL(600568.SH)